MBMarina Bortolami

Marina Bortolami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina Bortolami has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and “normal” liver tissues

    by Marina Bortolami, Alessandra Comparato, Clara Benna, Andrea Errico, Isacco Maretto, Salvatore Pucciarelli, Umberto Cillo, Fabio Farinati

    The physiological role of autophagy in the progression of liver diseases is still debated. To understand the clinical relevance of autophagy in primary e secondary hepatic tumors, we analyzed the expression of mTOR (mammalian target of rapamycin), a key regulator of autophagy; Raptor (regulatory-associated protein of mTOR); ULK1 (Unc-51 like kinase 1) determinant in the autophagy initiation; LC3 (microtubule-associated protein 1A/1B-light chain 3), a specific marker of autophagosomes; and p62, a selective autophagy receptor. Samples from subjects with chronic hepatitis (n.58), cirrhosis (n.12), hepatocellular carcinoma (HCC, n.56), metastases (n.48) from colorectal cancer and hyperplasia or gallbladder stones (n.7), the latter considered as controls, were examined. Gene expression analysis was carried out in n.213 tissues by absolute q-PCR, while protein expression by Western Blot in n.191 lysates, including tumoral, surrounding tumoral and normal tissues. Nonparametric statistical tests were used for comparing expression levels in the above-mentioned groups. Subgroup analysis was performed considering viral infection and chemotherapy treatment. The mTOR transcriptional level was significantly lower in metastases compared to HCC (P = 0.0001). p-mTOR(Ser2448) and LC3II/LC3I protein levels were significantly higher in metastases compared to HCC (P = 0.008 and PConclusions:the different expression of proteins considered, owning their interaction and diverse tissue microenvironment, indicate an impairment of the autophagy flux in primary liver tumors that is critical for the promotion of tumorigenesis process and a coexistence of autophagy inhibition and activation mechanisms in secondary liver tumors. Differences in mTOR and LC3 transcripts emerged in tumor-free tissues, therefore particular attention should be considered in selecting the control group.


  • Open Access

    Erratum to: Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma

    by Romilda Cardin, Marika Piciocchi, Alessandro Sinigaglia, Enrico Lavezzo, Marina Bortolami, Andromachi Kotsafti, Umberto Cillo, Giacomo Zanus, Claudia Mescoli, Massimo Rugge, et al.


  • Open Access

    Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma

    by Andromachi Kotsafti, Fabio Farinati, Romilda Cardin, Umberto Cillo, Donato Nitti, Marina Bortolami

    Background: Dysregulation of autophagy is important in the pathogenesis of many diseases, including cancer. Several aspects of the biological role of autophagy are however still unclear and the relationship between apoptosis and autophagy, particularly in the liver has yet to be thoroughly explored. In this study we evaluated the expression of Beclin 1 (one of the main autophagocytic agents, which bridges autophagy, apoptosis and both differentiation), and both pro- (Bad, Bax) and anti-apoptotic (Bcl-2, Bcl-xL) factors in liver samples from patients with different stages of liver disease. Methods: The study concerned 93 patients from 49 cases of chronic hepatitis (CH) (30 HCV and 19 HBV-related), 13 of cirrhosis (CIRR) (10 HCV and 3 HBV-related), 21 of hepatocellular carcinoma (both HCC and peritumoral tissues [PHCC]), and 10 controls (CONTR). Real-time PCR and Western blotting were used to measure mRNA and protein expression levels. Results: Beclin 1 mRNA levels were lower in HCC than in CH (P = 0.010) or CIRR (P = 0.011), and so were the Bcl-xL transcripts (P < 0.0001). Bad mRNA levels were higher in CH and CIRR than in CONTR, while Bax transcripts were increased in all tissues (P = 0.036). PHCC expressed the highest Bcl-2 mRNA levels. HBV-related CH tissues showed significantly higher Bcl-xL and Bad mRNA levels than HCV-related CH (P = 0.003 and P = 0.016, respectively). Conclusions: High Beclin 1, Bcl-xL and Bad levels in CH and CIRR tissues suggest an interaction between autophagy and apoptosis in the early and intermediate stages of viral hepatitis. In HCC these processes seem to be downregulated, probably enabling the survival and growth of neoplastic hepatocytes.


  • Open Access

    Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma

    by Cardin Romilda, Piciocchi Marika, Sinigaglia Alessandro, Lavezzo Enrico, Bortolami Marina, Kotsafti Andromachi, Cillo Umberto, Zanus Giacomo, Mescoli Claudia, Rugge Massimo, et al.

    MicroRNAs expression has been extensively studied in hepatocellular carcinoma but little is known regarding the relationship, if any, with inflammation, production of reactive oxygen species (ROS), host’s repair mechanisms and cell immortalization. This study aimed at assessing the extent of oxidative DNA damage (8-hydroxydeoxyguanosine - 8-OHdG) in different phases of the carcinogenetic process, in relation to DNA repair gene polymorphism, telomeric dysfunction and to the expression of several microRNAs, non-coding genes involved in post-transcriptional regulation, cell proliferation, differentiation and death. Tissue samples obtained either at surgery, [neoplastic (HCC) and adjacent non-cancerous cirrhotic tissues (NCCT)] at percutaneous or laparoscopic biopsy (patients with HCV or HBV-related hepatitis or patients undergoing cholecystectomy) were analysed for 8-OHdG (HPLC-ED), OGG1 (a DNA repair gene) polymorphism (PCR-RFLP), telomerase activity, telomere length (T/S, by RT-PCR), Taqman microRNA assay and Bad/Bax mRNA (RT-PCR). Fifty-eight samples from 29 HCC patients (obtained in both neoplastic and peritumoral tissues), 22 from chronic hepatitis (CH) and 10 controls (cholecystectomy patients - CON) were examined. Eight-OHdG levels were significantly higher in HCC and NCCT than in CH and CON (p=0.001). Telomerase activity was significantly higher in HCC than in the remaining subgroups (p=0.002); conversely T/S was significantly lower in HCC (p=0.05). MiR-199a-b, -195, -122, -92a and −145 were down-regulated in the majority of HCCs while miR-222 was up-regulated. A positive correlation was observed among 8-OHdG levels, disease stage, telomerase activity, OGG1 polymorphisms and ALT/GGT levels. In HCC, miR-92 expression correlated positively with telomerase activity, 8-OHdG levels and Bad/Bax mRNA. The above findings confirm the accumulation, in the progression of chronic liver damage to HCC, of a ROS-mediated oxidative DNA damage, and suggest that this correlates with induction of telomerase activity and, as a novel finding, with over-expression of miR-92, a microRNA that plays a role in both the apoptotic process and in cellular proliferation pathways.


  • Open Access

    P065 Mucosal immune environment in colonic carcinogenesis: CD80 over-expression in ulcerative colitis and dysplasia is associated to oxidative DNA damage and TLR4 expression

    by M. Scarpa, R. Cardin, M. Bortolami, A. Kotsafti, A. Pozza, G. Maran, M. Picciocchi, C. Ruffolo, R. D'Incà, I. Castagliuolo, et al.

    M. Scarpa, R. Cardin, M. Bortolami, A. Kotsafti, M. Scarpa, A. Pozza, G. Maran, M. Picciocchi, C. Ruffolo, R. D'Incà, I. Castagliuolo, G.C. Sturniolo, C. Castor

  • Open Access

    Bax Inhibitor-1 down-regulation in the progression of chronic liver diseases

    by Andromachi Kotsafti, Fabio Farinati, Romilda Cardin, Patrizia Burra, Marina Bortolami

    Background: Bax inhibitor-1 (BI-1) is an evolutionary conserved endoplasmic reticulum protein that, when overexpressed in mammalian cells, suppresses the apoptosis induced by Bax, a pro-apoptotic member of the Bcl-2 family. The aims of this study were: (1) to clarify the role of intrinsic anti- and pro-apoptotic mediators, evaluating Bax and BI-1 mRNA and protein expressions in liver tissues from patients with different degrees of liver damage; (2) to determine whether HCV and HBV infections modulate said expression. Methods: We examined 62 patients: 39 with chronic hepatitis (CH) (31 HCV-related and 8 HBV-related); 7 with cirrhosis (6 HCV-related and 1 HBV-related); 13 with hepatocellular carcinoma (HCC) [7 in viral cirrhosis (6 HCV- and 1 HBV-related), 6 in non-viral cirrhosis]; and 3 controls. Bax and BI-1 mRNAs were quantified by real-time PCR, and BI-1 protein expression by Western blot. Results: CH tissues expressed significantly higher BI-1 mRNA levels than cirrhotic tissues surrounding HCC (P < 0.0001) or HCC (P < 0.0001). Significantly higher Bax transcripts were observed in HCV-genotype-1-related than in HCV-genotype-3-related CH (P = 0.033). A positive correlation emerged between BI-1 and Bax transcripts in CH tissues, even when HCV-related CH and HCV-genotype-1-related CH were considered alone (P = 0.0007, P = 0.0005 and P = 0.0017, respectively). Conclusions: BI-1 expression is down-regulated as liver damage progresses. The high BI-1 mRNAs levels observed in early liver disease may protect virus-infected cells against apoptosis, while their progressive downregulation may facilitate hepatocellular carcinogenesis. HCV genotype seems to have a relevant role in Bax transcript expression.


  • Stathmin and apoptotic mediators in chronic HCV-related liver disease

    by A. Kotsafti, C. Carlotto, R. Cardin, F. Farinati, M. Bortolami

  • 513 HEPATOCELLULAR CARCINOMA (HCC) AND HEPATITIS VIRUSES: OXIDATIVE DAMAGE CORRELATE WITH CELL IMMORTALIZATION AND MIRNA EXPRESSION

    by R. Cardin, M. Bortolami, M. Piciocchi, L. Barzon, A. Sinigaglia, E. Lavezzi, U. Cillo, G. Zanus, F. Farinati

  • Fas / FasL system, IL‐1β expression and apoptosis in chronic HBV and HCV liver disease

    by M. Bortolami, A. Kotsafti, R. Cardin, F. Farinati

    Summary.  The Fas / Fas‐ligand (FasL) system is an important death signal pathway in the liver. An enhanced local inflammatory response prompted by FasL expression, which contributes to neutrophil recruitment and interleukin‐1 beta (IL‐1β) release, seems to be crucial to chronic liver damage, persistence of viral infections, and probably initiation and / or promotion of HCC. In order to evaluate the expression of Fas, FasL, and IL‐1β in different stages of human liver disease and to determine whether hepatitis B virus (HBV) and hepatitis C virus (HCV) infections modulate their expression, also in relation to apoptosis, we examined 87 liver samples obtained from patients with: chronic hepatitis (CH) (n.42), cirrhosis (n.9) and hepatocellular carcinoma (HCC) (n.16) and corresponding peritumoural tissues (n.16); histologically‐normal liver (n.4) as controls. Fas, FasL and IL‐1β mRNA were quantified using reverse transcriptase‐polymerase chain reaction. The apoptotic index was evaluated by TUNEL analysis. Our data showed a progressive Fas / FasL increase from CH to cirrhosis followed by a decline from the latter to HCC. In histological sections apoptosis was detected in HCC. A significant difference emerged between HCV and HBV‐related disease for IL‐1β expression only in CH. A significant positive correlation between IL‐1β and FasL in HCV‐related disease (P = 0.014) and an inverse correlation between IL‐1β and Fas in HBV‐related disease (P = 0.021) were observed. The different pattern of IL‐1β, Fas and FasL expression found in HCV‐ and HBV‐mediated liver disease, points to a different modulation of immune response B and C virus induced, while the decline in Fas / FasL expression in HCC may be related to defence mechanisms adopted by HCC cells against the immune system.


  • Open Access

    P292 TGF-BETA1 AND IGF-1 AND ANASTOMOTIC RECURRENCE OF CROHN'S DISEASE AFTER ILEO-COLONIC RESECTION

    by M. Scarpa, M. Bortolami, S. Morgan, A. Kotsafti, C. Ruffolo, R. D'Incà, E. Bertin, L. Polese, G.C. Sturniolo, D.F. D'Amico, et al.

    M. Scarpa, M. Bortolami, S. Morgan, A. Kotsafti, C. Ruffolo, R. D'Incà, E. Bertin, L. Polese, G.C. Sturniolo, D.F. D'Amico, I. Angriman; P292 TGF-Beta1 and IGF